JP2017527618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527618A5 JP2017527618A5 JP2017531987A JP2017531987A JP2017527618A5 JP 2017527618 A5 JP2017527618 A5 JP 2017527618A5 JP 2017531987 A JP2017531987 A JP 2017531987A JP 2017531987 A JP2017531987 A JP 2017531987A JP 2017527618 A5 JP2017527618 A5 JP 2017527618A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- mucolytic agent
- dnase
- amino acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 15
- 239000003172 expectorant agent Substances 0.000 claims 13
- 229940066491 mucolytics Drugs 0.000 claims 13
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102220608724 Suppressor of cytokine signaling 2_D53R_mutation Human genes 0.000 claims 7
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 5
- 102220551800 Polyglutamine-binding protein 1_Y65A_mutation Human genes 0.000 claims 5
- 102220589468 DNA repair protein XRCC4_E69R_mutation Human genes 0.000 claims 4
- 102220472023 Delta-aminolevulinic acid dehydratase_H44A_mutation Human genes 0.000 claims 4
- 101000863721 Homo sapiens Deoxyribonuclease-1 Proteins 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 108010067396 dornase alfa Proteins 0.000 claims 3
- 230000003301 hydrolyzing effect Effects 0.000 claims 3
- 102220547884 Apoptosis-associated speck-like protein containing a CARD_E13W_mutation Human genes 0.000 claims 2
- 102220470191 Aryl hydrocarbon receptor repressor_D53K_mutation Human genes 0.000 claims 2
- 102220518153 DNA-directed RNA polymerases I and III subunit RPAC1_E13R_mutation Human genes 0.000 claims 2
- 102220576075 HLA class I histocompatibility antigen, B alpha chain_E69T_mutation Human genes 0.000 claims 2
- 102220624351 Interferon alpha-8_V67E_mutation Human genes 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 102220344807 c.193T>A Human genes 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 102220282125 rs1060501223 Human genes 0.000 claims 2
- 102200143063 rs121908290 Human genes 0.000 claims 2
- 102220034815 rs199475569 Human genes 0.000 claims 2
- 102200070544 rs202198133 Human genes 0.000 claims 2
- 102200078878 rs490262 Human genes 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 102220547887 Apoptosis-associated speck-like protein containing a CARD_E13A_mutation Human genes 0.000 claims 1
- 102220547456 Arginine and glutamate-rich protein 1_S68R_mutation Human genes 0.000 claims 1
- 101100230463 Caenorhabditis elegans his-44 gene Proteins 0.000 claims 1
- 102220519703 Cytosolic phospholipase A2 gamma_H44N_mutation Human genes 0.000 claims 1
- 102220542222 Eukaryotic peptide chain release factor GTP-binding subunit ERF3B_L52K_mutation Human genes 0.000 claims 1
- 102220471819 Eukaryotic translation initiation factor 4E_S68K_mutation Human genes 0.000 claims 1
- 102220576074 HLA class I histocompatibility antigen, B alpha chain_E69M_mutation Human genes 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 102220520933 Linker for activation of T-cells family member 2_V48C_mutation Human genes 0.000 claims 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims 1
- 102220502777 Putative C->U-editing enzyme APOBEC-4_G49K_mutation Human genes 0.000 claims 1
- HBTSUHWXOLOLFW-UHFFFAOYSA-N [Na].[Na].OS(=O)(=O)CCSCCS(O)(=O)=O Chemical compound [Na].[Na].OS(=O)(=O)CCSCCS(O)(=O)=O HBTSUHWXOLOLFW-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 102220582114 rRNA-processing protein FCF1 homolog_Y65P_mutation Human genes 0.000 claims 1
- 102220003960 rs104894736 Human genes 0.000 claims 1
- 102200120948 rs1057520695 Human genes 0.000 claims 1
- 102200008576 rs121917899 Human genes 0.000 claims 1
- 102200045114 rs143793528 Human genes 0.000 claims 1
- 102200137585 rs151344616 Human genes 0.000 claims 1
- 102220281089 rs1555418261 Human genes 0.000 claims 1
- 102200014182 rs1555748926 Human genes 0.000 claims 1
- 102200097267 rs199472840 Human genes 0.000 claims 1
- 102200156936 rs28934878 Human genes 0.000 claims 1
- 102220237139 rs376184349 Human genes 0.000 claims 1
- 102200082875 rs63751285 Human genes 0.000 claims 1
- 102220316041 rs786202335 Human genes 0.000 claims 1
- 102220075958 rs796052446 Human genes 0.000 claims 1
- 102220089258 rs869312818 Human genes 0.000 claims 1
- 102220201545 rs886041401 Human genes 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047361P | 2014-09-08 | 2014-09-08 | |
| US62/047,361 | 2014-09-08 | ||
| PCT/US2015/048606 WO2016040169A2 (en) | 2014-09-08 | 2015-09-04 | Methods of treating pulmonary sarcoidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527618A JP2017527618A (ja) | 2017-09-21 |
| JP2017527618A5 true JP2017527618A5 (enExample) | 2019-02-14 |
Family
ID=54697634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531987A Pending JP2017527618A (ja) | 2014-09-08 | 2015-09-04 | 肺サルコイドーシスの治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9402884B2 (enExample) |
| EP (1) | EP3191090A2 (enExample) |
| JP (1) | JP2017527618A (enExample) |
| KR (1) | KR20170045750A (enExample) |
| CN (1) | CN107249621A (enExample) |
| AU (1) | AU2015315455A1 (enExample) |
| BR (1) | BR112017004533A2 (enExample) |
| CA (1) | CA2960622A1 (enExample) |
| IL (1) | IL250980A0 (enExample) |
| MX (1) | MX2017002948A (enExample) |
| WO (1) | WO2016040169A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| DK3668972T3 (da) | 2017-08-18 | 2025-01-13 | Neutrolis Inc | Konstruerede dnase-enzymer og anvendelse i terapi |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| IL325846A (en) | 2018-10-08 | 2026-03-01 | Neutrolis Inc | Engineering deoxyribonuclease enzymes for manufacturing and medicine |
| US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
| JP2022521600A (ja) * | 2019-02-22 | 2022-04-11 | シラ セラピューティック インコーポレイティッド | 吸入可能な治療剤 |
| WO2024197201A1 (en) * | 2023-03-22 | 2024-09-26 | The Regents Of The University Of California | Systems and methods for the quantitative assessment of airway mucus plug pathology |
| US20260109959A1 (en) * | 2025-01-18 | 2026-04-23 | Brian William Davies | Methods of treating pulmonary sarcoidosis with dna nucleases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| EP1004302A3 (en) * | 1998-10-29 | 2003-06-04 | Ajinomoto Co., Inc. | Immunomodulator |
| JP2007230919A (ja) * | 2006-03-01 | 2007-09-13 | Ki Pharma Kk | 美白剤 |
| BRPI0814449A2 (pt) * | 2007-08-03 | 2015-08-25 | Ucb Pharma Sa | Compostos e sais dos mesmos |
| US8236786B2 (en) * | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| NZ590774A (en) * | 2008-08-07 | 2012-09-28 | Pulmagen Therapeutics Inflammation Ltd | Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases |
| GB201014391D0 (en) * | 2010-08-27 | 2010-10-13 | Biocopea Ltd | Drug composition and its use in therapy |
| GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
| GB201002224D0 (en) * | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
-
2015
- 2015-09-04 CN CN201580060653.1A patent/CN107249621A/zh active Pending
- 2015-09-04 AU AU2015315455A patent/AU2015315455A1/en not_active Abandoned
- 2015-09-04 US US14/846,266 patent/US9402884B2/en not_active Expired - Fee Related
- 2015-09-04 WO PCT/US2015/048606 patent/WO2016040169A2/en not_active Ceased
- 2015-09-04 CA CA2960622A patent/CA2960622A1/en not_active Abandoned
- 2015-09-04 EP EP15798585.4A patent/EP3191090A2/en not_active Ceased
- 2015-09-04 MX MX2017002948A patent/MX2017002948A/es unknown
- 2015-09-04 JP JP2017531987A patent/JP2017527618A/ja active Pending
- 2015-09-04 US US15/508,191 patent/US20170368150A1/en not_active Abandoned
- 2015-09-04 BR BR112017004533A patent/BR112017004533A2/pt not_active IP Right Cessation
- 2015-09-04 KR KR1020177009617A patent/KR20170045750A/ko not_active Withdrawn
-
2017
- 2017-03-07 IL IL250980A patent/IL250980A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527618A5 (enExample) | ||
| JP2014051497A5 (enExample) | ||
| MX2022010870A (es) | Composicion que comprende lactoferrina y cepas bacterianas probioticas para uso oral con accion antiviral. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| JP2015517489A5 (enExample) | ||
| HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
| MX376012B (es) | Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas. | |
| EP4620525A3 (en) | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | |
| AR062453A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| EP4591936A3 (en) | Treatment of respiratory diseases | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| BR112017020039A2 (pt) | composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica | |
| BR112018000656A2 (pt) | peptídeos para uso na promoção do transporte de glicose | |
| WO2011094598A3 (en) | Compositions and methods for reversing corticosteroid resistance or treating respiratory infections | |
| MX2022003758A (es) | Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido. | |
| NZ783377A (en) | Pegylated novel molecules for agonising tlr2 | |
| WO2016040169A3 (en) | Mucolytic agents for use in tretaing pulmonary sarcoidosis | |
| BR112017018209A2 (pt) | produtos terapêuticos de polipeptídeo e usos dos mesmos | |
| JP2017529398A5 (enExample) | ||
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| CL2020000597A1 (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas. | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| JP2017517561A5 (enExample) | ||
| NZ609440A (en) | Preventative or therapeutic agent for fibrosis |